
50.64 Delayed Data As of May 26 | ![]() Today’s Change | 36.91 Today|||52-Week Range 57.82 | +4.56% Year-to-Date |
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar? May 29 / Zacks.com - Paid Partner Content | Regeneron (REGN) Faces Challenges as Eylea Sales Decline May 19 / Zacks.com - Paid Partner Content |
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study May 26 / Zacks.com - Paid Partner Content | Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote May 19 / Zacks.com - Paid Partner Content |
2 Bear Market Defying Stocks to Buy in May May 22 / MotleyFool.com - Paid Partner Content |
Previous close | 52.59 |
Today’s open | 52.89 |
Day’s range | 52.48 - 53.17 |
Volume | 1,268,692 |
Average volume (3 months) | 1,806,466 |
Market cap | $132.5B |
Earnings growth (last year) | +19.66% |
Earnings growth (this year) | +0.01% |
Earnings growth (next 5 years) | +7.80% |
Revenue growth (last year) | +1.25% |
P/E ratio | 14.7 |
Price/Sales | 2.69 |
Price/Book | 1.65 |
Today’s change | Today’s % change | |
---|---|---|
BMYBristol-Myers Squibb | -0.01 | -0.01% |
VRTXVertex Pharmaceutica... | -2.64 | -0.79% |
REGNRegeneron Pharmaceut... | +0.05 | +0.01% |
---- |
Next reporting date | July 28, 2023 |
EPS forecast (this quarter) | $0.89 |
Annual revenue (last year) | $45.2B |
Annual profit (last year) | $8.8B |
Net profit margin | 19.47% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Paris, Ile-de-france |